Get the Stockscreener App
2.31
0.86%
-0.02
Newcelx Ltd stock is traded at $2.31, with a volume of 36,969.
It is down -0.86% in the last 24 hours and down -36.54% over the past month.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
See More
Previous Close:
$2.33
Open:
$2.28
24h Volume:
36,969
Relative Volume:
0.55
Market Cap:
$10.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+21.58%
1M Performance:
-36.54%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.28
$2.4406
1-Week Range:
$1.9599
$2.70
52-Week Range:
$1.89
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.31 | 10.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newcelx Ltd Stock (NCEL) Latest News
NewcelX appoints Swiss pharma executive to scientific advisory board By Investing.com - Investing.com Nigeria
NewCelX Appoints EY as New Auditor Following Merger - MSN
NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board - MarketScreener
NewcelX Adds Swiss Diabetes Leader to Advisory Board to Steer IsletRx Program - TipRanks
NewcelX appoints Swiss pharma executive to scientific advisory board - Investing.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Nasdaq
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
NewcelX Ltd. (NCEL) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
NewcelX Strengthens IP Portfolio with Chinese Patent Publication - TipRanks
NewcelX strengthens IP portfolio with Chinese patent publication - MSN
NewcelX patent for neurological disease treatments published in China - Investing.com
NewcelX patent for neurological disease treatments published in China By Investing.com - Investing.com Canada
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Nasdaq
NewcelX Ltd. (NCEL) -8.5% in After-hours: Decline Amid Routine Trading Conditions - Stocks Telegraph
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Aktiellt
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) - Aktiellt
NewcelX Ltd.Ordinary Shares (NQ: NCEL - Markets Financial Content
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer) | NLSP SEC FilingForm 6-K - Stock Titan
NewcelX appoints ALS specialist to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX appoints ALS specialist to scientific advisory board - Investing.com
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Finviz
NewcelX Appoints Renowned Neurologist to Strengthen Scientific Advisory Board - TipRanks
Price to sales ratio of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Press Release: NewcelX Announces Scientific Leadership With the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - 富途牛牛
NewcelX Ltd. (NCEL) - Zacks Investment Research
NLS Pharmaceutics to execute 1-for-10 reverse share split - MSN
NewcelX Ltd. (NCEL) company profile and facts - Yahoo Finance UK
NewcelX Announces New CFO Appointment Following Merger - MSN
NewcelX Ltd. (NCEL) interactive stock chart - Yahoo Finance UK
NewcelX Ltd. (NCEL) Stock Forum & Discussion - Yahoo! Finance Canada
NewcelX Ltd (NCEL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NewcelX Ltd (NCEL) Stock Earnings Transcripts - GuruFocus
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 By Investing.com - Investing.com Australia
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 - Investing.com India
Neurology expert Prof. Ben-Hur joins NewcelX scientific board By Investing.com - Investing.com Nigeria
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewcelX Ltd. (NCEL) analyst ratings, estimates and forecasts - Yahoo Finance Australia
NewcelX Ltd. (NCEL) Income Statement - Yahoo! Finance Canada
NewcelX Ltd. (NCEL) valuation measures and financial statistics - Yahoo Finance Australia
NCEL Interactive Stock Chart | NewcelX Ltd. Stock - Yahoo Finance
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - WV News
Neurology expert Prof. Ben-Hur joins NewcelX scientific board - Investing.com
NewcelX Ltd. (NCEL) Stock Major Holders - Yahoo! Finance Canada
Newcelx Ltd Stock (NCEL) Financials Data
There is no financial data for Newcelx Ltd (NCEL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):